SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
pcn12111-sup-0001-si.ppt65K

Figure S1. Two male control subjects who are both physically and mentally healthy, aged 39 and 46 years old, underwent I-metaiodobenzylguanidine (I-MIBG) scintigraphy three times every 2 weeks. First, I-MIBG scintigraphy was performed without milnacipran. Then, the subjects took 25 mg and 75 mg milnacipran, respectively, 2 h before starting I-MIBG scintigraphy. This figure shows the heart-to-mediastinum (H/M) ratio in early images.

pcn12111-sup-0002-si.ppt65K

Figure S2. Two male control subjects who are both physically and mentally healthy, aged 39 and 46 years old, underwent I-metaiodobenzylguanidine (I-MIBG) scintigraphy three times every 2 weeks. First, I-MIBG scintigraphy was performed without milnacipran. Then, the subjects took 25 mg and 75 mg milnacipran, respectively, 2 h before starting I-MIBG scintigraphy. This figure shows the heart-to-mediastinum (H/M) ratio in delayed images.

pcn12111-sup-0003-si.ppt65K

Figure S3. Two male control subjects who are both physically and mentally healthy, aged 39 and 46 years old, underwent I-metaiodobenzylguanidine (I-MIBG) scintigraphy three times every 2 weeks. First, I-MIBG scintigraphy was performed without milnacipran. Then, the subjects took 25 mg and 75 mg milnacipran, respectively, 2 h before starting I-MIBG scintigraphy. This figure shows the wash-out rate (WR) (%).

pcn12111-sup-0004-si.docx11K

Table S1. Two male control subjects who are both physically and mentally healthy, aged 39 and 46 years old, underwent I-metaiodobenzylguanidine (I-MIBG) scintigraphy three times every 2 weeks. First, I-MIBG scintigraphy was performed without milnacipran. Then, the subjects took 25 mg and 75 mg milnacipran, respectively, 2 h before starting I-MIBG scintigraphy. This table shows the heart-to-mediastinum (H/M) ratio in early and delayed images and the wash-out rate (WR) (%).

pcn12111-sup-0005-si.xls23K

Table S2. Assessments of results of all the subjects with the criteria for the clinical diagnosis of dementia with Lewy bodies (DLB).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.